Skip to content

ADVANCED SOLID TUMOR 

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

VIEW HERE

Participating Practices:

  • University Cancer and Blood Center

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

VIEW HERE

Participating Practices:

  • Northwest Medical Specialties

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

VIEW HERE

 

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

VIEW HERE

 

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)

VIEW HERE

 


BLADDER

An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

VIEW HERE


BREAST

XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease

VIEW HERE

Participating Practices:

  • Highlands Oncology Group
  • Northwest Medical Specialties

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

VIEW HERE

 

An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )

VIEW HERE

Participating Practices:

  • Northwest Medical Specialties

 

A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease

VIEW HERE

Participating Practices:

  • Fort Wayne Medical Oncology and Hematology
  • New Jersey Cancer Care and Blood Disorders
  • Oklahoma Cancer Specialists and Research Institute
  • University Cancer and Blood Center
Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer (AMEERA-4)

VIEW HERE

Participating Practices:

  • Fort Wayne Medical Oncology and Hematology
  • New Jersey Cancer Care and Blood Disorders

COLORECTAL 

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

VIEW HERE

Participating Practices:

  • Fort Wayne Medical Oncology and Hematology
  • Nebraska Cancer Specialists
  • New Jersey Cancer Care and Blood Disorders
  • Northwest Medical Specialties
  • Oklahoma Cancer Specialists and Research Institute
  • Oregon Oncology Specialists
  • Pontchartrain Cancer Center
  • Stockton Hematology Oncology Medical Group
  • University Cancer and Blood Center
  • Virginia Cancer Institute

GASTROINTESTINAL

A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)

VIEW HERE

Participating Practices:

  • Pontchartrain Cancer Center

LUNG

A Phase II, Open-label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-doublet Chemotherapy in Patients Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-small Cell Lung Cancer

VIEW HERE

Participating Practices:

  • Highlands Oncology Group
  • University Cancer and Blood Center
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE

VIEW HERE

Participating Practices:

  • Highlands Oncology Group
  • Northwest Medical Specialties
  • Pontchartrain Cancer Center
  • University Cancer and Blood Center
  • Virginia Cancer Institute

LYMPHOMA

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma

VIEW HERE

 

A Phase 2a Open-label Study to Investigate Safety and Tolerability (Including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination With Lenalidomide in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

VIEW HERE

 

PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

VIEW HERE

Participating Practices:

  • Cancer Care Associates of York

MYELODYSPLASTIC SYNDROME

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

VIEW HERE

Participating Practices:

  • Pontchartrain Cancer Center
  • Virginia Cancer Institute

 

Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

VIEW HERE

Participating Practices:

  • Pontchartrain Cancer Center
  • Cancer Care Associates of York

NSCLC

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

VIEW HERE

 

A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2 Study)

VIEW HERE

 

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

VIEW HERE

Participating Practices:

  • New Jersey Cancer Care and Blood Disorders
  • Oregon Oncology Specialists
  • University Cancer and Blood Center

PROSTATE

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

VIEW HERE


TEMPUS PRIORITY STUDY

An Observational Study of Patients who have Received Comprehensive Genomic Profiling

Participating Practices:

  • Highlands Oncology Group
  • New Jersey Cancer Care and Blood Disorders
  • Pontchartrain Cancer Center

Sponsors and CROs please contact Rosemary McQueary, Director of Research at rmcqueary@qcca.us.com or 317-313-6879 for study placement and information on network capabilities.